Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.1935 USD -2.94% Market Closed
Market Cap: 97.1m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Cash Interest Paid
$1m
CAGR 3-Years
74%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Cash Interest Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
97.1m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.924 USD
Overvaluation 58%
Intrinsic Value
Price

See Also

What is Adagene Inc's Cash Interest Paid?
Cash Interest Paid
1m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Cash Interest Paid amounts to 1m USD.

What is Adagene Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
63%

Over the last year, the Cash Interest Paid growth was 75%. The average annual Cash Interest Paid growth rates for Adagene Inc have been 74% over the past three years , 63% over the past five years .

Back to Top